Citius Oncology Presents Positive Quality of Life Data for LYMPHIR®
Citius Oncology, Inc. announced positive health-related quality of life (HRQoL) results from its pivotal Study 302 of LYMPHIR® (denileukin diftitox-cxdl) in adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL). The data, presented at the EORTC-CLTG 2026 Annual Meeting, showed that patients who responded to LYMPHIR reported sustained improvements in skin-related quality of life measures, including reduced symptoms and improved emotional well-being. Additionally, a significant portion of heavily pretreated patients experienced a meaningful decrease in itch. These findings underscore the importance of quality of life considerations in CTCL treatment.
Key Highlights
- Citius Oncology presented health-related quality of life (HRQoL) results from pivotal Study 302 of LYMPHIR® (denileukin diftitox-cxdl).
- Patients who responded to LYMPHIR reported sustained improvement in skin-related quality of life measures.
- Among responders (n=25), mean change from baseline in Skindex-29 Total Score ranged from -5.38 to -13.69 points.
- Among responders, FACT-G Total Score showed a sustained benefit with a mean change from baseline of +3.21 at end of treatment.
- 32% (13/41) of heavily pretreated patients with significant itch noted a clinically meaningful decrease.
- Data was presented at the European Organisation for Research and Treatment of Cancer Cutaneous Lymphoma Tumour Group (EORTC-CLTG) 2026 Annual Meeting.
Price Impact
More from CTOR
Citius Oncology Expands Board, Appoints Jonathan Peri as Independent Director
Citius Oncology LYMPHIR New Accounts Up 78% Q/Q; $400M Market
Citius Oncology: LYMPHIR Combo Shows Promising Phase 1 Data in Gynecologic Cancers